Incannex Healthcare

Incannex Healthcare EBIT per Employee

EBIT per Employee of Incannex Healthcare (IXHL) as of Oct 28, 2026.

EBIT per Employee

-USD

Last updated:

EBIT per Employee of Incannex Healthcare is 2026 - USD. EBIT per Employee of Incannex Healthcare was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Incannex Healthcare Stock analysis

What does Incannex Healthcare do? Incannex Healthcare Inc develops medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for various medical conditions including obstructive sleep apnea, traumatic brain injury, and inflammatory diseases. The company operates with 28 distinct R&D programs and six ongoing clinical trials, focusing on treatments for conditions such as OSA, TBI, ARDS, COPD, rheumatoid arthritis, and anxiety disorders. Its portfolio includes specific clinical projects like IHL-42X for OSA, IHL-675A for lung and joint inflammation, IHL-216A for concussion and TBI, PSI-GAD for anxiety, and MedChew GB and MedChew -1401 for pain management. Incannex generates revenue through the development and potential commercialization of these pharmaceutical products, targeting healthcare providers and patients seeking innovative treatments for complex medical conditions. The company's primary revenue streams come from the progression of its R&D pipeline, with key products in clinical stages including IHL-42X, IHL-675A, IHL-216A, PSI-GAD, MedChew GB, and MedChew -1401. These products are developed for specific medical indications, such as obstructive sleep apnea, inflammatory lung diseases, rheumatoid arthritis, and pain disorders. Incannex's business model relies on securing funding through clinical trial partnerships and potential future licensing agreements with pharmaceutical companies, aiming to bring these therapies to market for patients requiring advanced treatment options. Incannex Healthcare Inc targets healthcare providers and patients in the pharmaceutical sector who are seeking novel therapies for conditions like sleep apnea, chronic pain, and inflammatory disorders. The company's diversified R&D portfolio, with six active clinical trials, positions it to address multiple unmet medical needs across various therapeutic areas. By focusing on cannabinoid-based and psychedelic medicine approaches, Incannex differentiates itself in the pharmaceutical market, aiming to provide innovative solutions for complex health challenges. Incannex Healthcare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Incannex Healthcare stock

On Eulerpool you can find the complete historical development of EBIT per Employee Incannex Healthcare since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Incannex Healthcare historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Incannex Healthcare

All Key Metrics — Incannex Healthcare